To further expand its global presence and ensure widespread vaccine availability, SII has established Serum Life Sciences Ltd, a subsidiary in the UK. Through relentless pursuit of innovation, SII ...
BioSpectrum India on MSN
Eveliqure and Serum Institute of India collaborate for development of anti-diarrhoeal vaccines
To accelerate clinical development and global access to critical vaccines for children ...
The Flying Dutchman on MSN
Is Rosengartenschlucht the most beautiful gorge in Austria?
Rosengartenschlucht is a stunning natural gorge located in Imst, Austria. The 1.5 km trail begins at the Blue Grotto and follows the Schinderbach River through steep rock formations. Visitors walk ...
Since 2021 Europe has seen increasing rates of invasive meningococcal disease, which is caused by a bacterial infection. The ...
Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 ...
Why models and longitudinal data on adherence to non-pharmaceutical interventions must come together
An interdisciplinary team of authors from Canada, Austria, the U.S. and Germany has outlined how immuno-epidemiology and individual decision-making on non-pharmaceutical interventions (NPIs) can be ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company’s ...
In a new clinical guideline, rapid practice points are presented for receipt of RSV protein subunit vaccines among adults.
Alpine monitors are reporting that all but two of Austria’s 96 glaciers have retreated over the last two years and say such a ...
Researchers at the Kennedy Institute of Rheumatology have found that physically resisting the formation of an immunological synapse actually promotes a stronger immune response. The findings could ...
Company leaders to engage the global research community on circular RNA, AI-driven therapeutics, and next-generation RNA platforms HOUSTON, TX, UNITED STATES, March ...
The Food and Drug Administration's decision, made public on Feb. 10, to not review an application to approve Moderna's proposed mRNA-based flu vaccine set off a firestorm of criticism from public ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results